Eliava Biopreparations
Eliava BioPreparations (EBP) is a Georgian biopharmaceutical company, which researches, develops, and manufactures therapeutic and prophylactic bacteriophage preparations for the treatment and prophylactics of bacterial infections.
EBP is part of the Eliava Consortium – a world-known center of excellence for bacteriophage research and application since 1923. In collaboration with the Eliava Institute and consortium member companies, EBP realizes the concept of the world’s first one-stop phage diagnostics, R&D, manufacturing, and application. Thus, continuing the vision of distinguished Georgian physician, bacteriologist, and phage researcher Prof. George Eliava.
Eliava Biopreparations holds the privilege to use scientific developments and produce the preparations developed by the Eliava Institute.
Today our product proudly carries a trademark “Developed by George Eliava Institute of Bacteriophages, Microbiology, and Virology”.
As the direct successor of the phage production of the Eliava Institute, EBP procures its products based on knowledge and experience of almost a century of continuous scientific research.
The Eliava BioPreparations team unites more than 30 scientists and phage production specialists, who work at the Eliava Institute. Being at the frontier of bacteriophage research, EBP has been awarded multiple international grants, including FP7 and Horizon 2020.
EBP products and solutions are used by patients and partners in more than 60 countries worldwide. Eliava Insitute, together with its group of companies uses bacteriophages to target the problem of bacterial resistance against different antibacterial remedies. We have the most advanced knowledge, and longest ongoing history, for the development and use of bacteriophages for science, therapy, veterinary, environmental care, and numerous other applications.
Eliava BioPreparations offers modern solutions to bacterial problems.
For viewing the products, please visit the link
Eliava Biopreparations
Eliava BioPreparations (EBP) is a Georgian biopharmaceutical company, which researches, develops, and manufactures therapeutic and prophylactic bacteriophage preparations for the treatment and prophylactics of bacterial infections.
EBP is part of the Eliava Consortium – a world-known center of excellence for bacteriophage research and application since 1923. In collaboration with the Eliava Institute and consortium member companies, EBP realizes the concept of the world’s first one-stop phage diagnostics, R&D, manufacturing, and application. Thus, continuing the vision of distinguished Georgian physician, bacteriologist, and phage researcher Prof. George Eliava.
Eliava Biopreparations holds the privilege to use scientific developments and produce the preparations developed by the Eliava Institute.
Today our product proudly carries a trademark “Developed by George Eliava Institute of Bacteriophages, Microbiology, and Virology”.
As the direct successor of the phage production of the Eliava Institute, EBP procures its products based on knowledge and experience of almost a century of continuous scientific research.
The Eliava BioPreparations team unites more than 30 scientists and phage production specialists, who work at the Eliava Institute. Being at the frontier of bacteriophage research, EBP has been awarded multiple international grants, including FP7 and Horizon 2020.
EBP products and solutions are used by patients and partners in more than 60 countries worldwide. Eliava Insitute, together with its group of companies uses bacteriophages to target the problem of bacterial resistance against different antibacterial remedies. We have the most advanced knowledge, and longest ongoing history, for the development and use of bacteriophages for science, therapy, veterinary, environmental care, and numerous other applications.
Eliava BioPreparations offers modern solutions to bacterial problems.
For viewing the products, please visit the link
